Bassan R, Brüggemann M, Radcliffe H-S et al (2019) A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica 104:2028–2039. https://doi.org/10.3324/haematol.2018.201053

Article  PubMed  PubMed Central  Google Scholar 

Agrwal S, Sahi PK (2020) National comprehensive cancer network guidelines for pediatric acute lymphoblastic leukemia. Indian Pediatr 57:561–564. https://doi.org/10.1007/s13312-020-1855-1

Article  PubMed  Google Scholar 

Key Statistics for Acute Lymphocytic Leukemia (ALL). https://www.cancer.org/cancer/acute-lymphocytic-leukemia/about/key-statistics.html. Accessed 14 Sept 2022

Van Dongen JJM, Van der Velden VHJ, Brüggemann M et al (2015) Minimal residual disease diagnostics in acute lymphoblastic leukemia: Need for sensitive, fast, and standardized technologies. Blood 125:3996–4009. https://doi.org/10.1182/blood-2015-03-580027

Article  CAS  PubMed  PubMed Central  Google Scholar 

Porwit A, Béné M-C (2011) CHAPTER 19: acute lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemias. In: Porwit A, McCullough J, Erber WN (eds) Blood and bone marrow pathology. Second Edition, pp 289–01

Overbergh L, Vig S, Coun F, et al. (2017) Chapter 4: quantitative polymerase chain reaction. In: Patrinos GP (ed) Molecular diagnostics. Third Edition, pp 41–58

Bradstock KF, Janossy G, Tidman N et al (1981) Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia. Leuk Res 5:301–309. https://doi.org/10.1016/0145-2126(81)90002-3

Article  CAS  PubMed  Google Scholar 

Greaves M, Delia D, Janossy G et al (1980) Acute lymphoblastic leukaemia associated antigen: IV: expression on non-leukaemic “lymphoid” cells. Leuk Res 4:15–32. https://doi.org/10.1016/0145-2126(80)90044-2

Article  CAS  PubMed  Google Scholar 

van Wering ER, van der Linden-Schrever BE, Szczepański T et al (2000) Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease. Br J Haematol 110:139–146. https://doi.org/10.1046/j.1365-2141.2000.02143.x

Article  PubMed  Google Scholar 

Patil PP, Jafa E, Aggarwal M (2021) Minimal residual disease in acute lymphoblastic leukemia. Indian J Med Paediatr Oncol 42:71–76. https://doi.org/10.1055/s-0041-1729730

Article  Google Scholar 

Della Starza I, Chiaretti S, De Propris MS et al (2019) Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances. Front Oncol 9:726. https://doi.org/10.3389/fonc.2019.00726

Article  PubMed  PubMed Central  Google Scholar 

Salzer WL, Burke MJ, Devidas M et al (2021) Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Children’s Oncology Group AALL1131. JCO 39:10004–10104. https://doi.org/10.1200/JCO.2021.39.15_suppl.10004

Article  Google Scholar 

Mortuza FY, Papaioannou M, Moreira IM et al (2002) Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 20:1094–1104. https://doi.org/10.1200/JCO.2002.20.4.1094

Article  PubMed  Google Scholar 

Lee S, Kim D-W, Cho B-S et al (2012) Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 26:2367–2374. https://doi.org/10.1038/leu.2012.164

Article  CAS  PubMed  Google Scholar 

Berry DA, Zhou S, Higley H et al (2017) Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol 3:e170580. https://doi.org/10.1001/jamaoncol.2017.0580

Article  PubMed  PubMed Central  Google Scholar 

Shen Z, Gu X, Mao W et al (2018) Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer 18:755. https://doi.org/10.1186/s12885-018-4670-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Panda SS, Radhakrishnan V, Ganesan P et al (2020) Flow cytometry based MRD and its impact on survival outcome in children and young adults with ALL: a Prospective Study from a Tertiary Cancer Centre in Southern India. Indian J Hematol Blood Transfus 36:300–308. https://doi.org/10.1007/s12288-019-01228-0

Article  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, The PRISMA et al (2020) statement: an updated guideline for reporting systematic reviews. BMJ. https://doi.org/10.1136/bmj.n71

Article  PubMed  Google Scholar 

Haddaway NR, Collins AM, Coughlin D, Kirk S (2015) The role of google scholar in evidence reviews and its applicability to grey literature searching. PLoS ONE 10:e0138237. https://doi.org/10.1371/journal.pone.0138237

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bommannan BKK, Arumugam JR, Sundersingh S et al (2019) CD19 negative and dim precursor B-lineage acute lymphoblastic leukemias: real-world challenges in a targeted-immunotherapy era. Leuk Lymphoma 60:3154–3160. https://doi.org/10.1080/10428194.2019.1625043

Article  CAS  PubMed  Google Scholar 

Ganesan P, Jain H, Bagal B et al (2021) Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC). Br J Haematol 2021:193. https://doi.org/10.1111/bjh.17268

Article  Google Scholar 

Bommannan K, Arumugam JR, Radhakrishnan V et al (2022) Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center. Hematol Transfus Cell Ther 44:143–150. https://doi.org/10.1016/j.htct.2020.08.012

Article  PubMed  Google Scholar 

Das N, Gupta R, Gupta SK et al (2020) A real-world perspective of CD123 expression in acute leukemia as promising biomarker to predict treatment outcome in B-ALL and AML. Clin Lymphoma Myeloma Leuk 20:e673–e684. https://doi.org/10.1016/j.clml.2020.05.004

Article  PubMed  Google Scholar 

Jain H, Sengar M, Goli VB et al (2021) Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia. Blood Adv 5:3436–3444. https://doi.org/10.1182/bloodadvances.2020003368

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jain P, Korula A, Deshpande P et al (2018) Adult acute lymphoblastic leukemia: limitations of intensification of therapy in a developing country. J Glob Oncol 4:1–12. https://doi.org/10.1200/JGO.17.00014

Article  PubMed  Google Scholar 

Virk H, Rana S, Sharma P et al (2021) Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort. Ann Hematol 100:2031–2041. https://doi.org/10.1007/s00277-021-04574-0

Article  CAS  PubMed  Google Scholar 

Pandey A, Ahlawat S, Singh A et al (2020) Outcomes and impact of minimal residual disease (MRD) in pediatric, adolescent and young adults (AYA) with acute lymphoblastic leukemia treated with modified MCP 841 protocol. Cancer Res Stat Treat 3:183. https://doi.org/10.4103/CRST.CRST_85_20

Article  Google Scholar 

Rajendra A, Jain H, Bonda VNA et al (2021) Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol. Blood Adv 5:1178–1193. https://doi.org/10.1182/bloodadvances.2020003526

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arunachalam AK, Janet NB, Korula A et al (2020) Prognostic value of MRD monitoring based on BCR-ABL1 copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia. Leuk Lymphoma 61:3468–3475. https://doi.org/10.1080/10428194.2020.1811272

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garg N, Gupta R, Kotru M (2021) CD34 is not expressed by blasts in a Tthird of B-ALL patients and its negativity is associated with aberrant marker expression: a retrospective analysis. Asian Pac J Cancer Prev 22:919–925. https://doi.org/10.31557/APJCP.2021.22.3.919

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patkar N, Alex AAB et al (2012) Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country. Cytometry B Clin Cytom 82:252–258. https://doi.org/10.1002/cyto.b.21017

Article  PubMed  Google Scholar 

Chatterjee G, Dudakia V, Ghogale S et al (2021) Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment. Int J Lab Hematol 43:990–999. https://doi.org/10.1111/ijlh.13456

Article  PubMed  Google Scholar 

Das N, Gupta R, Gupta SK et al (2021) Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL. Ann Hematol 100(10):2487–2500. https://doi.org/10.1007/s00277-021-04580-2

Article  CAS  PubMed  Google Scholar 

Aboobacker F, Korula A, Devasia A, et al (2019) Allogeneic stem cell transplantation for acute lymphoblastic leukemia: A single centre experience. In: 60th annual conference of indian society of hematology & blood transfusion (ISHBT) October 2019. Indian J Hematol Blood Transfus, vol 35, pp 1–51. https://doi.org/10.1007/s12288-019-01207-5

Lakshmy CV, George B, Korula A, et al (2021) Utility of a low intensity bortezomib based regimen to induce remission in patients with relapsed acute lymphoblastic leukemia. In: 62nd annual conference of indian society of hematology & blood transfusion (ISHBT). Indian J Hematol Blood Transfus, vol 37, pp 1–172. https://doi.org/10.1007/s12288-021-01510-0.

Özcan M, Cassaday RD, Singh P et al (2021) The efficacy and safety of low-dose inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia: Interim results of a phase 4 study. Blood 138:1208–1308. https://doi.org/10.1182/blood-2021-15000

Article  Google Scholar 

Bhandary C, Prabhu M, Kar R, Basu D (2020) Expression of leukemia associated immunophenotype markers at diagnosis by 10 color flow cytometry in B cell precursor acute lymphoblastic leukemia for optimization of minimal residual disease panel. In: 61st Annual Conference of Indian Society of Hematology & Blood Transfusion (ISHBT) November 2020. Indian J Hematol Blood Transfus, vol 36, pp 1–229. https://doi.org/10.1007/s12288-020-01384-8

Meganathan D, Aakif M, Priyanka M, et al (2021) Advantages of 12 colour panel for acute leukemia diagnosis: data from a single centre in adolescent and adult population. In: 62nd annual conference of indian society of hematology & blood transfusion (ISHBT). Indian J Hematol Blood Transfus, vol 37, pp 1–172. https://doi.org/10.1007/s12288-021-01510-0

Vatsala BK, Sridevi BH, Nirupama M, et al (2020) Diagnostic role of flow cytometry in immunophenotyping of adult acute lymphoblastic leukemia. In: 61st annual conference of indian society of hematology & blood transfusion (ISHBT) November 2020. Indian J Hematol Blood Transfus, vol 36, pp 1–229. https://doi.org/10.1007/s12288-020-01384-8

Mazumder S, Manivannan P, Kar R, et al (2021) Optimization of a ten-colour antibody panel for measurable residual disease detection in B cell precursor acute lymphoblastic leukemia based on leukemia associated immunophenotype at diagnosis. In: 62nd annual conference of indian society of hematology & blood transfusion (ISHBT). Indian J Hematol Blood Transfus, vol 37, pp 1–172. https://doi.org/10.1007/s12288-021-01510-0

Dhar L, Singh S, Tanwar P, et al (2021) Significance of expression of CD38, CD58, CD49D AND CD66C in acute lymphoblastic leukemia. In: 62nd annual conference of indian society of hematology & blood transfusion (ISHBT). Indian J Hematol Blood Transfus, vol 37, pp 1–172. https://doi.org/10.1007/s12288-021-01510-0

Arunachalam AK, Kathirvel K, Kamruddin F, et al (2019) Clinical significance of end induction MRD monitoring in B Cell ALL: A single centre experience. In: 60th annual conference of indian society of hematology & blood transfusion (ISHBT) October 2019. Indian J Hematol Blood Transfus, vol 35, pp 1–151. https://doi.org/10.1007/s12288-019-01207-5

Brüggemann M, Gökbuget N, Kneba M (2012) Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Semin Oncol 39:47–57. https://doi.org/10.1053/j.seminoncol.2011.11.009

Article  CAS  PubMed